Articles tagged with Liver Cancer
A large cohort study found that high vitamin E intake from diet or supplements is associated with a lower risk of liver cancer. The study included over 132,000 individuals and analyzed data from two population-based cohort studies conducted in China.
A recent study published in the Journal of the National Cancer Institute found that high vitamin E intake from diet or supplements is associated with lower liver cancer risk. The analysis included 132,837 individuals and showed a clear inverse dose-response relation between vitamin E intake and liver cancer risk.
Researchers created a mouse model to study the role of AEG-1 in hepatocellular carcinoma, demonstrating its acceleration of disease progression and angiogenesis. The study paves the way for novel therapies targeting AEG-1.
Dr. Curtis Wray has been awarded a $729,000 grant to study disparities in liver cancer life expectancy among underserved populations. His research aims to identify factors contributing to the lower life expectancy of advanced liver cancer patients in these communities.
A recent study found that Alzheimer's patients who undergo hospitalization are at risk for complications such as delirium, loss of independence, and death. Researchers also highlighted the risks associated with Flavocoxid, a medical food used to treat osteoarthritis, which can cause liver injury in some patients. Additionally, screenin...
Scientists have made a significant breakthrough in understanding the cause of bile duct cancer by identifying several new genes frequently mutated in the disease. The research team discovered mutations in 187 genes using state-of-the-art DNA sequencing, shedding light on the molecular mechanisms of the disease.
A new biomarker has been identified to detect hepatitis B-infected patients at risk of developing liver cancer. Telomere length analysis revealed a significant association between longer telomeres and increased risk of liver cancer in patients with hepatitis B.
Researchers found that metformin reduces the level of glucose and inhibits fatty acid synthesis in mice, resulting in significantly fewer and smaller liver tumors. The drug has been linked to reduced risk of liver cancer in patients with Type II diabetes and obesity.
Wilmot researchers develop first genetically engineered mouse model for Intrahepatic Cholangiocarcinoma (IHCC), a type of bile duct cancer. The model incorporates common mutations in humans and enables testing of potential treatments, accelerating the discovery process.
Cancer tumors' metabolic profiles vary based on genes and tissue origin, necessitating individualized treatment approaches. The metabolome, in addition to the genome, is crucial for predicting metabolic changes and guiding therapy.
Researchers discovered a new commonality of chromosomal aberrations among embryonic cancers, including kidney, skeleton, and liver cancers. This finding could reveal the nature and progression of many different kinds of cancer by identifying patterns of mutation in the genome.
Mice genetically engineered to lack Foxa genes show reversed gender-related incidence of liver cancer, highlighting the protective role of estrogens against liver cancer. The study suggests that genetic markers called SNPs within Foxa binding sites may contribute to increased liver cancer risk in women.
The American Cancer Society's annual report shows a decline in cancer incidence and death rates, particularly among African American men and women. The report also highlights increasing trends in certain cancers, such as pancreatic and liver cancer, which may be linked to obesity and early detection practices.
Recent Mayo Clinic studies identify risk factors for rising liver cancer cases, including hepatitis C infection and fatty liver disease. The studies suggest that screening for hepatitis C could improve treatment and survival rates for affected populations.
A new study shows that targeting a specific microRNA, miR-221, can prolong the lives of mice with human liver cancer. The treatment also boosted activity of tumor-suppressor genes in these animals.
Dana-Farber Cancer Institute researchers have identified a mechanism that triggers inflammation in the liver and transforms normal cells into cancerous ones. They demonstrated that a particular micro-RNA, miR-124, can be harnessed to treat or prevent liver cancer.
Recent studies have uncovered significant limitations in liver cancer screening for patients with cirrhosis, emphasizing the need for enhanced diagnostic procedures. Most patients with cirrhosis prefer surveillance over non-screening, and ultrasonographic screening at different intervals did not improve detection of small liver cancers.
A study found that organ transplant recipients have a doubled cancer risk compared to the general population, with increased risks for various types of malignancies, including non-Hodgkin lymphoma and lung cancer. The increased risk is attributed to immunosuppression and oncogenic viral infections.
Two new studies advance the field of yttrium-90 radioembolization for liver cancer treatment. Researchers successfully modified blood vessels to maximize tumor-killing material delivery and simplify treatment. This technique allows for high local radiation doses with minimal risk to healthy tissues.
A new study reveals liver cancer incidence rates are rising in North America and Oceania, while declining in some Asian countries. Despite this, liver cancer remains a significant health issue in these regions, with high rates of infection and limited effective treatments.
Researchers tested a combination of oral drug sorafenib and microbead chemotherapy directly into tumors in advanced liver cancer patients. The treatment showed promise with no increased side effects compared to existing therapies.
Researchers at the University of Hawaii Cancer Center and The Queen's Medical Center will analyze gene expression and imaging data to detect liver cancer earlier. They aim to improve patient outcomes and reduce deaths from this deadly disease.
Researchers found that saffron significantly reduced the number and incidence of liver nodules, with complete inhibition observed at the highest dose. Saffron also inhibited the elevation of proteins indicating liver damage and blocked inflammation.
Inhibiting heat shock transcription factor 1 (HSF1) prevents liver cancer in mice by reducing access to glucose and lipids, which are critical for tumor growth. This finding supports the idea that altering metabolism can be an effective cancer treatment.
A new imaging technology reveals that metabolic shifts in cancer cells occur even before detectable tumors form, suggesting an early diagnostic tool for liver cancer. The study also shows that tumor metabolism changes precede tumor regression, offering potential strategies for cancer treatment and more effective therapies.
Leeds researchers investigate the effectiveness of pure Eicosapentaenoic Acid (EPA) in preventing the spread of bowel cancer to the liver. Previous studies have shown that EPA may prevent large bowel polyps, a precursor to colorectal cancer.
Researchers discover that celecoxib triggers liver cancer cell death by inhibiting a key protein, and combining it with chemotherapy drugs boosts effectiveness. The study suggests the possibility of a new treatment approach for liver cancer, which has a low five-year survival rate.
A recent study published in Gastroenterology highlights the increased risk of gastrointestinal complications in childhood cancer survivors after therapy. Risks for colostomy/ileostomy, cirrhosis or liver biopsy were highest among older patients and those exposed to abdominal radiation or certain chemotherapy treatments.
Boulton's research highlights include discovering key genes and enzymes involved in DNA repair mechanisms, including RTEL1 and ALC1. His work has led to novel therapeutic approaches for cancer treatment, particularly liver cancer.
The number of AIDS-defining cancers decreased, while non-AIDS-defining cancers increased significantly between 1991-2005. Lung cancer emerged as the most common malignancy in people with HIV but not AIDS.
A study found that diabetes is associated with a lower risk of prostate cancer in men, but a higher risk of other cancers and mortality in both men and women. Diabetes was linked to increased risks for colon, rectal, and liver cancers in men and women.
Researchers found that individuals with metabolic syndrome are at higher risk for developing liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The study, presented at the AACR 102nd Annual Meeting, highlights the importance of metabolic syndrome in increasing liver cancer incidence.
A four-year study confirms that Y-90 radioembolization is a safe and effective treatment for patients with metastatic liver cancer, particularly those who have failed chemotherapy. The procedure preserves patient quality of life and extends life, while also demonstrating anti-tumoral effects.
Researchers at VCU Massey Cancer Center have discovered a novel mechanism in gene regulation that contributes to the development of liver cancer. AEG-1 and SND1 proteins were found to increase RISC activity, leading to increased tumor growth. Inhibiting SND1 is proposed as a potential new avenue for treating liver cancer.
A long-term study found that consuming three or more drinks a day is associated with an increased risk of pancreatic cancer death in both men and women. Heavy drinking, specifically liquor consumption, also shows a significant association with pancreatic cancer mortality, particularly among never smokers.
A study at Cold Spring Harbor Laboratory has identified a therapeutic target for liver cancer using a monoclonal antibody that blocks the activity of the FGF19 gene. This approach shows promise in treating patients with FGF19 amplification, which can be used as a biomarker to predict treatment effectiveness.
A recent study found racial disparities in liver cancer survival rates, with black patients experiencing higher mortality rates compared to white and Hispanic patients. Despite receiving similar treatments, black patients had a 12% increased rate of death, indicating poor access to care and subpar treatment outcomes.
A new study found that black patients with early-stage liver cancer have a higher mortality rate than white patients, with median survival times ranging from 8-10 months. The disparity in treatment access also affects the survival rates of Hispanic and black patients compared to white patients.
Groopman's research identified the link between environmental carcinogens and liver cancer, providing new prospects for prevention in high-risk populations worldwide. His work elucidated the role of aflatoxins in inducing hepatocellular carcinoma, a major cause of mortality in developing countries.
Researchers have found a synthetic molecule, LLL12, that blocks activation of the oncogene STAT3 in liver cancer cells, halting their survival and increasing sensitivity to chemotherapy. This discovery offers potential for an anti-cancer therapy option.
The study found significant disparities in survival rates among Asian-Americans diagnosed with liver cancer, with Laotian/Hmong-Americans having the lowest median survival rate of just one month. The group was also least likely to receive treatment, such as liver transplantation, due to late-stage diagnoses.
Researchers at Columbia University have found that ROCK2 may be a good therapeutic target for treating autoimmune disorders, while targeting CD13+ CSCs in liver cancer could provide a new treatment approach. Additionally, scientists at Stanford University developed ways to enhance RNAi efficacy and persistence while decreasing toxicity.
A case report describes a rare instance of intrahepatic clear cell cholangiocarcinoma, highlighting its distinct characteristics and low risk of metastasis. The cancer's unique cell structure and lack of mucin production set it apart from conventional HCCs.
A study published in Hepatology found that fewer than 20% of patients with cirrhosis and hepatocellular carcinoma received regular surveillance. Despite high-risk patients being recommended for HCC surveillance, population-based studies indicate only 11% are diagnosed early enough to receive potentially curative treatments.
A rare case of intrahepatic clear cell cholangiocarcinoma was reported in a Japanese man with hepatitis B virus (HBV) infection. The cancer cells were larger than usual and lacked mucin, differing from conventional ICC cases.
A study at Baylor College of Medicine found that eliminating tumor suppressor C/EBP alpha is key to cancer development in the aging liver. Another protein, gankyrin, is elevated first, leading to degradation of C/EBP alpha and allowing uncontrolled growth.
A University of Rochester study found a direct link between the androgen receptor and hepatitis B virus in causing liver cancer, explaining why men get the disease more often than women. Researchers showed that targeting the androgen receptor could lead to new treatment approaches for patients with hepatocellular carcinoma.
A University of Illinois study demonstrates that agronomic practices can significantly increase the cancer-fighting compounds in broccoli and tomatoes. Selenium-treated broccoli was found to have six times higher levels of one compound and exhibited increased bioactivity, particularly in the liver.
Researchers have developed a system that uses real-time X-ray images to visualize tumors and minimize radiation damage to surrounding tissues. The tool allows for precise targeting of radiotherapy, increasing the dose of radiation administered to lung and liver cancers.
Virginia Commonwealth University researchers identified a new tumor-promoting gene called LSF, which is significantly higher in more than 90% of patients with liver cancer compared to healthy individuals. Inhibiting LSF may reverse the aggressive properties of human liver cancer cells.
Researchers discovered that immune suppressive cells in the liver may facilitate cancer spread, and targeting these cells could prevent it. Combating immune suppressive cells early after cancer development may keep the disease from spreading to the liver.
A new treatment using intra-arterial yttrium-90 microspheres has shown promising results in extending the lives of patients with hepatocellular carcinoma, particularly those with portal vein thrombosis. The treatment offers a minimally invasive option for patients who cannot undergo surgery.
Research at the University of California, San Diego, reveals that obesity is a tumor-promoting factor for liver cancer, primarily through chronic inflammation caused by cytokines like IL-6 and TNF. This effect may be preventable with anti-TNF drugs, which also reduce liver fat accumulation.
Researchers identified a protein switch that helps prevent liver damage and cancer, offering new insights into the development of liver disease and cancer. The study suggests that TAK1 could be a master regulator of liver function, and its role in liver disease and cancer may enable the development of new therapeutic strategies.
A new study published in the American Journal of Roentgenology found that combining triple-drug TACE with a liver transplant significantly increased long-term survival rates for patients with unresectable liver cancer. The median survival time for patients who underwent the procedure was over 112 months.
A 20-year study revealed a significant drop in liver cancer cases among vaccinated 6- to 19-year-olds. The universal vaccination program in Taiwan has been shown to extend its effectiveness into young adulthood.
Researchers discovered Alc1's chromatin remodeling enzyme activity is strongly activated by NAD and Parp1. This suggests a mechanism for Parp1 and poly(ADP-ribose) to function in transcriptional regulation, DNA repair, and DNA replication
A chemical found in blueberry leaves has shown a strong effect in blocking the replication of the Hepatitis C virus, which affects 200 million people worldwide. The compound, proanthocyanidin, is similar to chemicals found in grapes and wine and is considered safe as a dietary supplement.
Two genes, AEG-1 and LSF, contribute to chemotherapy resistance in liver cancer treatment. The study found that over-expression of AEG-1 increases resistance to 5-fluorouracil, a commonly used chemotherapeutic drug.
A large meta-analysis found certain HBV DNA mutations associated with HCC development and more prevalent in chronic HBV infection progression. The study may help predict liver cancer risk in patients with HBV infections.